Fig. 1
GRIM 19 blocks alloreactive T cell responses both in vitro and in vivo. a In the mixed lymphocyte reaction (MLR) assay, a total of 105 RBC-lysed B6 or GRIM19 splenic T cells (responders) were incubated with 105 irradiated RBC-lysed Balb/c splenic APCs (allogeneic [allo] stimulators) or B6 splenic APCs (syngeneic [syn] stimulators) for 4 days. T cell proliferation was measured through 3[H]-TdR incorporation. b IL-17 levels were determined in supernatants using ELISA. Data represent the mean ± SD of triplicate experiments. Data are representative of at least three independent experiments. c Recipients (B/c mice) were intravenously injected with 5 × 106 donor (WT or GRIM19 Tg) bone marrow cells and 1 × 107 splenocytes after lethal irradiation. Data are representatives of at least three independent experiments. GVHD clinical manifestations after allogeneic BMT were scored for weight loss, posture, activity, fur texture, and skin integrity. The combined data from two independent experiments (n = 20 per group). **p < 0.01 compared to GVHD control